BORA PHARMACEUTICALS CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 756 TWD | -0.13% |
|
+3.42% | +18.31% |
| Sales 2024 * | 18.43B 566M | Sales 2025 * | 21.46B 659M | Capitalization | 76.51B 2.35B |
|---|---|---|---|---|---|
| Net income 2024 * | 3.22B 98.71M | Net income 2025 * | 4.71B 144M | EV / Sales 2024 * | 4.47 x |
| Net Debt 2024 * | 5.88B 181M | Net Debt 2025 * | 1.2B 36.95M | EV / Sales 2025 * | 3.62 x |
| P/E ratio 2024 * |
23.8
x | P/E ratio 2025 * |
16.3
x | Employees | - |
| Yield 2024 * |
1.79% | Yield 2025 * |
1.7% | Free-Float | 56.72% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -0.13% | ||
| 1 week | +3.42% | ||
| Current month | +15.77% | ||
| 1 month | +20.96% | ||
| 3 months | +14.89% | ||
| 6 months | +29.45% | ||
| Current year | +18.31% |
1 week
704.00
771.00
1 month
622.00845.00
Current year
612.00845.00
1 year
534.30845.00
3 years
101.09845.00
5 years
43.18845.00
10 years
10.31845.00
| Managers | Title | Age | Since |
|---|---|---|---|
Pao Hsi Sheng
CEO | Chief Executive Officer | - | 09-10-20 |
Chin Chu Wang
DFI | Director of Finance/CFO | - | 13-04-30 |
Raymond Lee
CTO | Chief Tech/Sci/R&D Officer | - | 18-06-24 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Shang Hung Shen
BRD | Director/Board Member | 65 | 14-08-25 |
Kuan Pai Chen
BRD | Director/Board Member | - | 19-06-10 |
Pao Hsi Sheng
CEO | Chief Executive Officer | - | 09-10-20 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.02% | 4 M€ | -4.41% | - | |
| 0.00% | 117 M€ | +0.16% | - | |
| 0.00% | 34 M€ | +2.22% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 756 | -0.13% | 1,559,104 |
| 24-04-24 | 757 | +0.80% | 2,719,260 |
| 24-04-23 | 751 | +4.60% | 4,612,175 |
| 24-04-22 | 718 | +1.70% | 2,771,903 |
| 24-04-19 | 706 | -3.42% | 4,383,141 |
End-of-day quote Taiwan S.E., April 24, 2024
More quotes
Bora Pharmaceuticals Co Ltd is a Taiwan-based company principally engaged in the agency and sales of western medicines, as well as the research, development, manufacture and sales of new drugs and health products. The Company's main products are categorized into prescription drugs and health care products, including central nervous drugs, cardiovascular drugs, antibiotics, antiviral agents, ophthalmic drugs, gastrointestinal drugs, foam ingots and health care products. In addition, the Company has biopharmaceutical technologies related to the development of cell lines for the production of protein drugs, the development and analysis of upstream and downstream processes, as well as the establishment of quality control and testing specifications and the creation of cell banks.
Sector
Pharmaceuticals
Calendar
2024-04-28
- Extraordinary Shareholders Meeting
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
756
TWD
Average target price
865
TWD
Spread / Average Target
+14.42%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +18.31% | 2.35B | |
| +25.23% | 556B | |
| -6.33% | 354B | |
| +19.90% | 331B | |
| +7.95% | 296B | |
| +13.00% | 233B | |
| +5.29% | 201B | |
| -10.35% | 193B | |
| -12.26% | 143B | |
| -6.47% | 144B |
- Stock Market
- Equities
- 6472 Stock
